HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alan M Fogelman Selected Research

Ezetimibe (Zetia)

1/2017Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alan M Fogelman Research Topics

Disease

64Atherosclerosis
10/2019 - 01/2002
40Inflammation (Inflammations)
01/2022 - 04/2002
11Neoplasms (Cancer)
01/2021 - 11/2010
10Coronary Disease (Coronary Heart Disease)
11/2017 - 08/2002
8Dyslipidemias (Dyslipidemia)
10/2019 - 07/2007
7Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 10/2003
5Coronary Artery Disease (Coronary Atherosclerosis)
01/2014 - 08/2002
4Atherosclerotic Plaque (Atheroma)
12/2020 - 12/2004
4Ovarian Neoplasms (Ovarian Cancer)
12/2018 - 11/2010
4Human Influenza (Influenza)
11/2008 - 08/2002
4Infections
08/2008 - 08/2002
3Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2022 - 01/2017
3HIV Infections (HIV Infection)
01/2022 - 02/2011
3Chronic Kidney Failure (Chronic Renal Failure)
06/2011 - 08/2009
3Rheumatoid Arthritis
10/2009 - 08/2006
3Cognitive Dysfunction
11/2008 - 10/2006
2Lung Neoplasms (Lung Cancer)
01/2021 - 01/2018
2Pulmonary Hypertension
01/2020 - 08/2014
2Carcinogenesis
10/2019 - 01/2018
2Obesity
01/2019 - 04/2007
2Reperfusion Injury
01/2019 - 12/2013
2Hypercholesterolemia
01/2017 - 01/2014
2Adenocarcinoma
11/2016 - 11/2010
2Vascular Diseases (Vascular Disease)
12/2015 - 08/2014
2Pulmonary Arterial Hypertension
12/2015 - 08/2014
2Hypoxia (Hypoxemia)
08/2014 - 08/2012
2Acute-Phase Reaction
04/2011 - 08/2006
2Proteinuria
11/2010 - 01/2010
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2010 - 08/2006
2Arthritis (Polyarthritis)
01/2009 - 05/2008
1Dysbiosis
01/2022
1Melanoma (Melanoma, Malignant)
12/2020
1Glucose Intolerance
01/2019
1Infarction (Infarctions)
01/2019
1Myocardial Ischemia (Ischemic Heart Diseases)
01/2019
1Breast Neoplasms (Breast Cancer)
11/2016

Drug/Important Bio-Agent (IBA)

46Peptides (Polypeptides)IBA
01/2022 - 01/2002
42Apolipoprotein A-I (Apolipoprotein A1)IBA
01/2022 - 01/2002
28LipidsIBA
01/2020 - 08/2002
20HDL LipoproteinsIBA
01/2016 - 10/2003
19ApolipoproteinsIBA
01/2021 - 10/2003
18CholesterolIBA
10/2019 - 01/2002
13Phospholipids (Phosphatides)FDA LinkGeneric
01/2022 - 08/2002
12Proteins (Proteins, Gene)FDA Link
01/2022 - 11/2005
12HDL CholesterolIBA
11/2016 - 08/2002
11AntioxidantsIBA
01/2022 - 10/2004
11Apolipoproteins E (ApoE)IBA
01/2016 - 09/2004
10Lipoproteins (Lipoprotein)IBA
01/2021 - 06/2004
10LDL Receptors (LDL Receptor)IBA
10/2019 - 08/2002
10Aryldialkylphosphatase (Paraoxonase)IBA
01/2019 - 08/2002
10oxidized low density lipoproteinIBA
11/2016 - 08/2002
8lysophosphatidic acidIBA
04/2015 - 11/2010
5EnzymesIBA
10/2019 - 11/2005
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2017 - 12/2003
4Insulin (Novolin)FDA Link
01/2019 - 12/2010
4Reactive Oxygen Species (Oxygen Radicals)IBA
01/2019 - 06/2004
4Interleukin-6 (Interleukin 6)IBA
10/2018 - 08/2002
4Biomarkers (Surrogate Marker)IBA
06/2012 - 08/2006
4LDL Lipoproteins (beta Lipoproteins)IBA
06/2011 - 06/2004
4Amino AcidsFDA Link
01/2009 - 01/2002
3oxidized- L- alpha- 1- palmitoyl- 2- arachidonoyl- sn- glycero- 3- phosphorylcholineIBA
11/2015 - 04/2002
3Triglycerides (Triacylglycerol)IBA
08/2015 - 01/2008
3apolipoprotein A-I mimetic peptide 4FIBA
08/2014 - 01/2009
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2022 - 11/2019
2lipopolysaccharide-binding proteinIBA
01/2021 - 10/2018
2EndotoxinsIBA
01/2021 - 11/2019
2AcidsIBA
01/2020 - 08/2014
2Serum Amyloid A Protein (Serum Amyloid A)IBA
10/2018 - 04/2013
2Lysophosphatidylcholines (Lysophosphatidylcholine)IBA
01/2017 - 04/2015
2Particulate MatterIBA
01/2017 - 06/2013
2HemopexinIBA
01/2016 - 07/2009
2Oxidants (Oxidizing Agents)IBA
12/2015 - 08/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2012 - 04/2011
2Liver X ReceptorsIBA
06/2012 - 10/2003
2Arachidonic Acid (Vitamin F)IBA
12/2010 - 06/2004
2Fatty Acids (Saturated Fatty Acids)IBA
12/2010 - 08/2008
2Pravastatin (Pravachol)FDA LinkGeneric
01/2010 - 05/2008
2ChemokinesIBA
01/2010 - 05/2008
2CytokinesIBA
05/2008 - 11/2004
2LDL CholesterolIBA
09/2003 - 08/2002
1Pharmaceutical PreparationsIBA
01/2021
1Lipopolysaccharide ReceptorsIBA
01/2021
115-hydroxy-5,8,11,13-eicosatetraenoic acidIBA
01/2020
1CholatesIBA
11/2019
1Interleukin-10 (Interleukin 10)IBA
11/2019
1Piroxicam (Feldene)FDA LinkGeneric
11/2019
1lipoxin A4IBA
11/2019
1IntegrinsIBA
10/2019
1stearoyl-coenzyme A (stearoyl-CoA)IBA
10/2019
1CalciumIBA
01/2019
1Insulin-Like Growth Factor I (IGF-1)IBA
12/2018
1Toll-Like Receptor 4IBA
10/2018
1LysophospholipidsIBA
01/2017
1Cholestanol (Coprostanol)IBA
01/2017
1Ezetimibe (Zetia)FDA Link
01/2017
1Tumor Viral Antigens (Large T Antigen)IBA
11/2016
1Chymases (Chymase)IBA
02/2016

Therapy/Procedure

13Therapeutics
01/2021 - 01/2005
3Oral Administration
08/2006 - 01/2002
2Art Therapy
01/2022 - 01/2021